{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T02:41:55Z","timestamp":1784774515616,"version":"3.55.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.jpba.2021.114351","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T12:12:17Z","timestamp":1630411937000},"page":"114351","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["LC-MS\/MS studies for identification and characterization of new forced degradation products of dabrafenib and establishment of their degradation pathway"],"prefix":"10.1016","volume":"206","author":[{"given":"Parul","family":"Grover","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Bhardwaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lovekesh","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2021.114351_bib1","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.jpba.2021.114351_bib2","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s12020-013-0139-0","article-title":"BRAF mutation assessment in papillary thyroid cancer: are we ready to use it in clinical practice?","volume":"45","author":"Puxeddu","year":"2014","journal-title":"Endocrine"},{"key":"10.1016\/j.jpba.2021.114351_bib3","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/codi.12427","article-title":"BRAF mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta\u2010analysis","volume":"15","author":"Clancy","year":"2013","journal-title":"Colorectal Dis."},{"key":"10.1016\/j.jpba.2021.114351_bib4","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa1014209","article-title":"BRAF mutations in hairy-cell leukemia","volume":"364","author":"Tiacci","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2021.114351_bib5","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng.2868","article-title":"Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas","volume":"46","author":"Brastianos","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jpba.2021.114351_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1479-5876-10-85","article-title":"The role of BRAF V600 mutation in melanoma","volume":"10","author":"Ascierto","year":"2012","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.jpba.2021.114351_bib7","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1038\/sj.onc.1210421","article-title":"MAP kinase signalling pathways in cancer","volume":"26","author":"Dhillon","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.jpba.2021.114351_bib8","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jpba.2021.114351_bib9","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10637-017-0502-8","article-title":"Safety, tolerability, and pharmacokinetic profile of dabrafenib in Japanese patients with BRAF V600 mutation-positive solid tumors: a phase 1 study","volume":"36","author":"Fujiwara","year":"2018","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.jpba.2021.114351_bib10","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jchromb.2013.02.025","article-title":"Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor dabrafenib in mouse plasma","volume":"925","author":"Sparidans","year":"2013","journal-title":"J. Chromatogr. B."},{"key":"10.1016\/j.jpba.2021.114351_bib11","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1007\/s00216-017-0316-8","article-title":"Simple and cost-effective liquid chromatography-mass spectrometry method to measure dabrafenib quantitatively and six metabolites semi-quantitatively in human plasma","volume":"409","author":"Vikingsson","year":"2017","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jpba.2021.114351_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113718","article-title":"Simultaneous quantification of dabrafenib, hydroxy-dabrafenib and trametinib in human plasma by liquid chromatography-tandem mass spectrometry","volume":"193","author":"Balakirouchenane","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2021.114351_bib13","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.1002\/bmc.4758","article-title":"Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC\u2013MS\/MS","volume":"34","author":"Krens","year":"2020","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jpba.2021.114351_bib14","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00216-020-03031-7","article-title":"Development and validation of a sensitive liquid chromatography tandem mass spectrometry assay for the simultaneous determination of ten kinase inhibitors in human serum and plasma","volume":"413","author":"Aghai","year":"2021","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jpba.2021.114351_bib15","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jpba.2016.03.049","article-title":"Simultaneous quantification of dabrafenib and trametinib in human plasma using high-performance liquid chromatography\u2013tandem mass spectrometry","volume":"125","author":"Nijenhuis","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2021.114351_bib16","doi-asserted-by":"crossref","first-page":"958","DOI":"10.36468\/pharmaceutical-sciences.727","article-title":"Development and validation of novel and highly sensitive stability-indicating reverse phase ultra performance liquid chromatography method for quantification of ibrutinib and its ten degradation products","volume":"82","author":"Mehta","year":"2020","journal-title":"Indian J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2021.114351_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113768","article-title":"LC and LC\u2013MS\/MS studies for identification and characterization of new degradation products of ibrutinib and elucidation of their degradation pathway","volume":"194","author":"Mehta","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2021.114351_bib18","first-page":"1","article-title":"Identification and characterization of new degradation products of belinostat using UHPLC-Q-TOF-MS\/MS and in silico toxicity prediction","author":"Mehta","year":"2021","journal-title":"J. Liq. Chromatogr. Relat. Technol."},{"key":"10.1016\/j.jpba.2021.114351_bib19","unstructured":"Q3A (R2) ICH Impurities in new drug substances International Conference on Harmonisation (ICH). Geneva, Switzerland."},{"key":"10.1016\/j.jpba.2021.114351_bib20","unstructured":"Q3B (R2) ICH Impurities in new drug products International Conference on Harmonisation (ICH). Geneva, Switzerland."},{"key":"10.1016\/j.jpba.2021.114351_bib21","unstructured":"Q1A (R2) ICH Stability testing of new drug substances and products International Conference on Harmonisation (ICH). Geneva, Switzerland."},{"key":"10.1016\/j.jpba.2021.114351_bib22","unstructured":"Q1B ICH Photostability testing of new drug substances and products International Conference on Harmonisation (ICH). Geneva, Switzerland."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708521004623?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708521004623?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:14:19Z","timestamp":1760001259000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708521004623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":22,"alternative-id":["S0731708521004623"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2021.114351","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"LC-MS\/MS studies for identification and characterization of new forced degradation products of dabrafenib and establishment of their degradation pathway","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2021.114351","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114351"}}